Bristol-Myers Squibb

Aches And Pains Shouldn't Obscure Achillion's Potential

Aches And Pains Shouldn't Obscure Achillion's Potential

Seeking Alpha

Stocks Could Rise For Companies Investing In Immunotherapy Treatments

Stocks Could Rise For Companies Investing In Immunotherapy Treatments

Seeking Alpha

Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?

Can Johnson & Johnson Hold Its Ground in the Multiple Myeloma Market?

Motley Fool

Reckitt in $482 mln deal to sell Bristol drugs in LatAm

Reckitt in $482 mln deal to sell Bristol drugs in LatAm

Reuters

U.S. court invalidates patent on Bristol hepatitis B drug

U.S. court invalidates patent on Bristol hepatitis B drug

Reuters

Big Pharma's Uphill 2013 Battle

Big Pharma's Uphill 2013 Battle

Motley Fool

What Will Type 2 Diabetes Treatments Look Like in 5 Years?

What Will Type 2 Diabetes Treatments Look Like in 5 Years?

Motley Fool

Pfizer, Bristol-Myers, Johnson And Johnson: Do They Have The Next Plavix, Or Vioxx?

Pfizer, Bristol-Myers, Johnson And Johnson: Do They Have The Next Plavix, Or Vioxx?

Seeking Alpha

AstraZeneca, Bristol-Myers’s Forxiga Not Backed by NICE

AstraZeneca, Bristol-Myers’s Forxiga Not Backed by NICE

Bloomberg

Two Peas in a Pharma Pod

Two Peas in a Pharma Pod

Motley Fool